Introduction {#Sec1}
============

Spindle cell neoplasm are diverse in nature by means of clinicopathologic and tumor biological heterogeneity^[@CR1]^. Primary spindle cell sarcoma (SCS) is an extremely rare entity and one of the least reported tumor^[@CR2]^. It is a type of connective tissue tumor and generally begins in layers of connective tissue such as that under the skin, between muscles, and surrounding organs. Only a handful of cases have been reported around the world from variety of body parts^[@CR3]--[@CR9]^. As such, SCS constitutes a diagnostic and therapeutic challenge^[@CR10],[@CR11]^.

As morbidity, majority of the previous reports were single case reports and retrospective case series with more than five patients were even few. According to these case reports, the clinical presentations of SCS were similar to the benign lesion at early stage^[@CR11]--[@CR18]^. Like other sarcoma, SCS were treated aggressively with surgical therapy as a mainstay in the management and adjuvant (chemo) radiotherapy was implemented for patients with high risk behavior^[@CR2],[@CR5],[@CR7],[@CR9],[@CR10],[@CR13],[@CR15]--[@CR18]^.

Nowadays, the sophisticated molecular pathologic diagnostic techniques has made the diagnosis of SCS accurate and reliable^[@CR2]^. However, owing to the rarity of SCS, there are lack of basic information regarding the tumor incidence, distinctive clinical characteristics, treatment outcome and disease specific prognostic factors. To address these, a retrospective investigation was carried out with study population from Surveillance, Epidemiology, and End Results (SEER) database.

Results {#Sec2}
=======

Summary statistics {#Sec3}
------------------

A total of 3299 cases were identified. The average follow-up time was 43 months (SD = 65), with the median follow-up time was 15 months (range, 1--481 months). Of these patients, the mean age at diagnosis of patients was 61 years (SD = 19, range from birth to 103 years) (Fig. [1](#Fig1){ref-type="fig"}). The incidence peaked during the seventh decade of life and the majority of cases were white people (80.9%, 2668/3299). There is no significant difference for gender distribution including 1605 females and 1694 males. According to this dataset, SCS could occur at almost any site of the body. The incidence was higher in superficial primary tumor site than internal primary tumor site (2041 vs. 1151 cases). More than 60% of overall case were treated surgery alone.Figure 1The distribution of age (**A**) and primary tumor site (**B**) of all SCS cases.

Among 3229 cases, 2115 cases were found with SCS specific mortality, in which included 1026 female and 1089 male with median age was 57 years (SD = 19). In this disease specific survival (DSS) group, white people account for nearly 80% of population (79.1%, 1674/2115). Regarding the pathological diagnosis, poorly differentiated cases were 27.5% (357/1300) and undifferentiated cases were 42.6% (554/1300). There were 302 early stage cases (AJCC stage I + II) and 367 advanced stage cases (AJCC stage III + IV). The basic clinic-pathological characteristics of overall study population and DSS subgroup summarized in Table [1](#Tab1){ref-type="table"}.Table 1Epidemiological and clinico-pathologic characteristics of SCS patients.CharacteristicDisease specific survivalOverall survivalAliveDeadTotal*P* valueAliveDeadTotal*P* valueGender0.2700.088  Female416610102651010951605  Male416673108949212021694Age\<0.001\<0.001  ≤64620665128570510001705  \>6421261883029712971594Race\<0.001\<0.001  White6531021167479418742668  Black86171257105270375Others748916384146230Pathologic grade\<0.001\<0.001  I6629957263135  II193101294220212432  III126231357161385546  IV195359554243630873AJCC Stage\<0.001\<0.001  I1362916517174245  II1102713714669215  III8686172105158263  IV2317219535267302T stage\<0.001\<0.001  Tx + T090188278116333449  T116239201218112330  T2228250478269424693  T34162052429  T42161822830N stage\<0.001\<0.001  Nx + N04744589325918411432  N1124456197291  N2077088M stage\<0.001\<0.001  Mx + M04653147795816271208  M12119521629294323SEER historic stage\<0.001\<0.001  Localized5122587706226491271  Regional209311520246547793  Distant4348252553722775Marital status0.9720.238  Married428659108752611951721  Others404624102847611021578Surgery\<0.001\<0.001  Performed703577128084511722017  Not performed10968078913510781213Site\<0.001\<0.001  Internal1965517472299221151  Superficial629658128776412772041

Survival analysis {#Sec4}
-----------------

Survival analysis were performed as previously described^[@CR19],[@CR20]^. There were significant differences depending on age (*P* \< *0.001*), marital status (*P* = 0.042), pathologic grade (*P* \< *0.001*), AJCC stage (*P* \< *0.001*), T stage (*P* \< *0.001*), N stage (*P* \< *0.001*), M stage (*P* \< *0.001*), SEER historic stage (*P* \< *0.001*), tumor site (*P* \< *0.001*) and treatment modality (*P* \< *0.001*) in overall survival (OS) **(**Fig. [2](#Fig2){ref-type="fig"}). While, the significant differences were also found DSS for age (*P* \< *0.001*), pathologic grade (*P* \< *0.001*), AJCC stage (*P* \< *0.001*), T stage (*P* \< *0.001*), N stage (*P* \< *0.001*), M stage (*P* \< *0.001*), SEER historic stage (*P* \< *0.001*), tumor site (*P* \< *0.001*) and treatment modality (*P* \< *0.001*) (Fig. [3](#Fig3){ref-type="fig"}).Figure 2Kaplan--Meier curves for overall survival compared by age (**A**), marital status (**B**), pathologic grade (**C**), surgery (**D**), AJCC stage (**E**), T stage (**F**), N stage (**G**), M stage (**H**), SEER historic stage (**I**), tumor site (**J**). SEER data 1973--2017.Figure 3Kaplan--Meier curves for disease specific survival compared by age (**A**), marital status (**B**), pathologic grade (**C**), surgery (**D**), AJCC stage (**E**), T stage (**F**), N stage (**G**), M stage (**H**), SEER historic stage (**I**), tumor site (**J**). SEER data 1973--2017.

In the univariate cox regression analysis, age, race, pathologic grade, AJCC stage, T stage, N stage, M stage, SEER historic and stage treatment were associated with DSS and OS (Table [2](#Tab2){ref-type="table"}). More importantly, the age \>64 years \[HR 95% CI: 2.149 (1.619--2.851), *P* \< *0.001*, age ≤64 years -- as Ref\], AJCC stage III \[HR 95% CI: 2.803 (1.352--5.813), *P* = 0.006, AJCC stage I -- as Ref\], and non-surgical treatment \[HR 95% CI: 2.979 (2.154--4.120), *P* \< *0.001*, surgery -- as Ref\] were independently associated with worse DSS. Besides, the age, marital status, AJCC stage, T stage, N stage, SEER historic stage, tumor location and treatment were also independently correlated with OS (Table [3](#Tab3){ref-type="table"}).Table 2Univariate Cox proportional hazard regression models.CharacteristicDisease specific survivalOverall survivalHR(95% CI)*P* valueHR(95% CI)*P* value**Gender**Female1.00 Reference1.00 ReferenceMale1.049(0.940--1.171)0.3921.054(0.971--1.145)0.205**Age**≤641.00 Reference1.00 Reference\>642.203(1.971--2.462)\<0.0012.039(1.874--2.218)\<0.001**Race**White1.00 Reference1.00 ReferenceBlack1.105(0.940--1.299)0.2281.036(0.912--1.178)0.583Others0.793(0.640--0.982)0.0340.878(0.745--1.035)0.122**Pathologic grade**I1.00 Reference1.00 ReferenceII1.136(0.752--1.717)0.5461.097(0.828--1.454)0.517III3.028(2.056--4.458)\<0.0012.342(1.793--3.060)\<0.001IV3.156(2.160--4.612)\<0.0012.477(1.910--3.212)\<0.001**AJCC Stage**I1.00 Reference1.00 ReferenceII1.202(0.711--2.030)0.4921.103(0.795--1.532)0.557III3.636(2.384--5.544)\<0.0012.602(1.973--3.432)\<0.001IV11.170(7.494--16.649)\<0.0016.379(4.912--8.284)\<0.001**T stage**Tx + T01.00 Reference1.00 ReferenceT10.187(0.132--0.264)\<0.0010.289(0.233--0.359)\<0.001T20.658(0.544--0.795)\<0.0010.693(0.600--0.800)\<0.001T31.103(0.662--1.837)0.7080.891(0.588--1.349)0.584T41.669(1.000--2.785)0.0501.387(0.943--2.041)0.097**N stage**Nx + N01.00 Reference1.00 ReferenceN12.482(1.817--3.391)\<0.0011.996(1.567--2.543)\<0.001N23.554(1.680--7.518)0.0012.258(1.125--4.531)0.022**M stage**Mx + M01.00 Reference1.00 ReferenceM14.575(3.802--5.507)\<0.0013.707(3.211--4.279)\<0.001**SEER historic stage**Localized1.00 Reference1.00 ReferenceRegional2.249(1.906--2.654)\<0.0011.759(1.569--1.972)\<0.001Distant6.532(5.587--7.636)\<0.0014.755(4.255--5.312)\<0.001**Marital status**Married1.00 Reference1.00 ReferenceOthers1.069(0.958--1.193)0.2301.087(1.002--1.180)0.045**Surgery**Performed1.00 Reference1.00 ReferenceNot performed4.242(3.783--4.758)\<0.0013.533(3.243--3.850)\<0.001**Site**Internal1.00 Reference1.00 ReferenceSuperficial0.552(0.492--0.618)\<0.0010.630(0.579--0.686)\<0.001Table 3Multivariate Cox proportional hazard regression models.CharacteristicDisease specific survivalOverall survivalHR(95% CI)*P* valueHR(95% CI)*P* value**Age**≤641.00 Reference1.00 Reference\>642.149(1.619--2.851)\<0.0012.133(1.737--2.618)\<0.001**AJCC Stage**I1.00 Reference1.00 ReferenceIII2.803(1.352--5.813)0.0061.662(1.023--2.699)0.040**T stage**Tx + T0------1.00 ReferenceT1------0.447(0.283--0.705)0.001T2------0.671(0.484--0.931)0.017**N stage**Nx + N0------1.00 ReferenceN1------1.557(1.049--2.312)0.028**SEER historic stage**Localized1.00 Reference1.00 ReferenceRegional1.588(1.082--2.330)0.018------Distant4.020(1.590--10.164)0.0033.347(1.584--7.071)0.002**Marital status**Married------1.00 ReferenceOthers------1.242(1.015--1.521)0.035**Surgery**Performed1.00 Reference1.00 ReferenceNot performed2.979(2.154--4.120)\<0.0012.810(2.215--3.565)\<0.001**Site**Internal1.00 Reference1.00 ReferenceSuperficial0.473(0.333--0.673)\<0.0010.552(0.427--0.715)\<0.001

Discussion {#Sec5}
==========

According to current investigation, SCS affects people of almost all ages which was as same as soft tissue sarcomas^[@CR21]^. SCS occur more commonly in middle and old age adult groups. In this series, SCS most frequently occurs during the seventh decades of life with the mean age at diagnosis of SCS is 61 years. In addition, there is no statistically significant difference on incidence rate in gender. However, there is predominance in male with a sex predilection of 1.11:1 male: female ratio in a previous report^[@CR22]^. Besides, the overall race distribution includes 80.9% white, 11.4% black, 7.8% American Indian/Asian/Pacific Islander (Table [1](#Tab1){ref-type="table"}). According to the survival analyses depending on demographic factors such as age, gender and race, it demonstrates that only age is an independent prognostic indicator for SCS in DSS and OS.

The treatment modalities were performed for SCS varied, including surgery, adjuvant radiotherapy and chemotherapy in previous available reports. In this study, we only concentrate on the obtainable treatment modality (surgery or not) and hopefully to confirm the role of surgery in SCS treatment. Despite of the difference in surgical style, the surgery group have absolute favorable survival in DSS and OS than non-surgery group. Thus, it indicates that surgical resection remains the mainstay of treatment for SCS. However, the value of extensive radical operation and lymphadenectomy is still ambiguous. Similarly, the descriptive results should not be misinterpreted as causal effects of surgery on survival because of the unavoidable severe treatment selection bias present in this retrospective data source. In addition, the use of adjuvant radiotherapy for SCS remains controversial, and the sensitivity of SCS to chemotherapy in the metastatic setting is highly variable^[@CR23]^. Unfortunately, due to the lack of information on other therapies in this study, we are unable to determine the conclusion from this data that SCS patients cannot benefit from radiotherapy or chemotherapy.

The pathologic grade and TNM/AJCC stage are associated with outcome of sarcomas and it is important for treatment protocol planning^[@CR24]--[@CR26]^. In this study, although the pathologic grading data in this study was incomplete and half of them were missing in the SEER database, there are still 1986 cases available. According to the SEER Program user's instruction, cases were listed with latest pathological grading system. Although two histological grading systems are mainly used for soft-tissue sarcoma: the National Cancer Institute (NCI) system and the French Federation of Cancer Centers Sarcoma Group (FNCLCC) system, but there is still no specific system can be used for spindle cell sarcoma. So we used the four-tiered grading system which was most commonly used, and recommended by the American Joint Commission on Cancer (National Cancer Institute, "Tumor Grade", accessed 18 August, 2014)^[@CR27]^. SCS were divided into four different pathologic grades basing on the degree of the cell differentiation^[@CR28]^. In results, most of the cases are advanced grade at the first time when they are diagnosed, which includes 546 cases at grade III (pathologically poorly differentiated, 27.5%) and 873 cares at grade IV (pathologically undifferentiated, 42.6%). Previous reports demonstrated pathologic grade is a significant prognostic factor for outcome in soft tissue sarcomas^[@CR29]^. Similarly the typical survival differences are found in pathologic grade for both DSS and OS (Figs [2](#Fig2){ref-type="fig"}[C](#Fig2){ref-type="fig"} and [3C](#Fig3){ref-type="fig"}). Meanwhile, for TNM stage/AJCC stage survival analysis relatively complete data are available, including 1531cases for TNM staging data 1025 cases AJCC staging. By performing survival analysis, the significant survival difference in OS and DSS have been presented in T stage, N stage, M stage and AJCC stage (Figs [2E--H](#Fig2){ref-type="fig"} and [3E--H](#Fig3){ref-type="fig"}). Importantly, AJCC stage is one of the independent prognostic factors for SCS in DSS. Similarly, we confirmed SEER historic stage was another independent prognostic indicator for SCS patients. In this results, the SEER stage of distant metastasized tumor was unfavorably associated with DSS and OS for SCS (Localized tumor - as a ref).

The tumor origination is another important factor affecting the outcome of the tumor. SCS can occur in any anatomic location including soft tissue, bone, or viscera^[@CR30]^. This study included all of the cases listed as spindle cell sarcoma which were pathologically confirmed (International Classification of Diseases for Oncology, Third Edition, Histologic Type ICD-O-3: 8801) including bone origination, meanwhile excluded undifferentiated high-grade pleomorphic sarcoma (8830/3) which is new category recognizes pleomorphic sarcomas that cannot be classified into any of the other categories. Above all, our study is the largest series of patients and intend to evaluate the primary tumor location as a prognostic factor for the first time. As previous studies, SCS occurred at any location of the body involving skin and subcutaneous connective tissue, tongue, sinus, trachea, atrium, vein, bone, etc.^[@CR11],[@CR31],[@CR32]^. For better characterization and further evaluating, we categorized the tumor locations into two main groups according to the distribution of primary tumor site: superficial site (tumor involving skin and subcutaneous soft tissue in head & neck, upper limb & shoulder, lower limb & hip, thorax & breast, abdomen, pelvis, trunk and other) and interior site (included tumor involving bone or viscera of digestive system, respiratory system, reproductive system, locomotors system, urinary system, nervous system, endocrine system, circulatory system). In this categorization (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}), we found that SCS was more likely to occur in the superficial site compare with the deep interior site (2014 superficial site cases versus 1151 interior site cases). And significant survival differences were found in both DSS and OS for SCS (Figs [2J](#Fig2){ref-type="fig"} and [3J](#Fig3){ref-type="fig"}). More importantly, tumor site is another independent prognostic indicator for SCS in both DSS and OS which means primary SCS locates in superficial site possibly have a better outcome.Table 4The distribution characteristics of SCS.CharacteristicDisease specific survivalOverall survivalAliveDeadTotal*P* valueAliveDeadTotal*P* valueSuperficial site (Subcutaneous, other soft tissue)\<0.001\<0.001Head & Face & Neck734912290159249Upper limb & Shoulder12159180144123267Lower limb & Hip224163387255310565Thorax & Breast92128220133219352Abdomen369713339162201Pelvis517612761155216Trunk243256306191Overlap and Other854621288100Internal site (Includes bone or viscera *et al*.)0.0070.003Digestive system429914149178227Respiratory system5015120160248308Reproductive system27669328106134Locomotor system2940693886124Urinary system124254166379Nervous system9162593342Endocrine system2464610Circulatory system2121421618Peritoneum& Spleen2312114423186209Table 5Univariate Cox proportional hazard regression models of tumor sites.CharacteristicDisease specific survivalOverall survivalHR(95% CI)*P* valueHR(95% CI)*P* value**Superficial site (Subcutaneous, other soft tissue)**Head & Face & Neck1.00 Reference1.00 ReferenceUpper limb & Shoulder0.814(0.556--1.192)0.2900.708(0.559--0.896)0.004Lower limb & Hip1.149(0.832--1.585)0.3990.906(0.748--1.098)0.314Thorax & Breast1.803(1.294--2.513)\<0.0011.128(0.919--1.384)0.249Abdomen3.170(2.241--4.484)\<0.0012.210(1.775--2.752)\<0.001Pelvis2.097(1.461--3.011)\<0.0011.678(1.343--2.096)\<0.001Trunk1.803(1.152--2.821)0.0101.313(0.977--1.765)0.071Overlap and Other5.059(3.410--7.508)\<0.0013.018(2.317--3.391)\<0.001**Internal site (Includes bone or viscera** ***et al*** *.* **)**Digestive system1.00 Reference1.00 ReferenceRespiratory system1.312(1.017--1.693)0.0371.121(0.924--1.359)0.248Reproductive system1.113(0.814--1.521)0.5021.076(0.846--1.369)0.551Locomotor system0.734(0.508--1.061)0.1000.900(0.696--1.165)0.425Urinary system1.369(0.953--1967)0.0891.235(0.926--1.647)0.150Nervous system0.962(0.567--1.633)0.8871.065(0.734--1.544)0.740Endocrine system1.537(0.565--4.180)0.4000.946(0.419--2.136)0.893Circulatory system2.297(1.149--3.827)0.0161.901(1.138--3.174)0.014Peritoneum& Spleen1.370(1.050--1.789)0.0211.252(1.019--1.539)0.033

The several important limitations that come with this study were acknowledged. Most importantly, the use of other treatment modalities is not recorded in the SEER database. Thus we could not identify the role of other treatment modalities, like radiotherapy or chemotherapy, in treatment for SCS. Besides, there are lack of information neither about surgery type nor resection margin status of the tumor. Similarly, it should be noted that some other important data specifically relevant to the tumor including TNM stage, AJCC stage, margin status, local or distant recurrence, lymphatic metastasis status, are either incomplete or absent. Additionally, we have to point out that the follow-up time in SEER is not even and long enough. However, this study is the first using such a large and comprehensive representative registry database to demonstrate the demographic features, clinic-pathologic characteristics, prognostic factors of spindle cell sarcoma.

In summary, it is definitely the largest data about SCS which came from SEER database. Despite its preliminary character, this study can clearly indicate the information on demographic features, distinctive clinicopathologic characteristics, tumor specific prognostic factors and treatment outcome by performing comprehensive analysis of the 3299 SCS cases from the database. The study does demonstrate that SCS mostly occurred during fifth to seventh decade of life in white people without gender specific. More importantly, we found that the ageå 64 years (≤64 years - as a ref), AJCC stage III (AJCC stage I - as a ref), SEER historic stage distant metastasized tumor (Localized tumor - as a ref) and primary tumor site in internal site (Tumor locate in superficial site - as a ref) were independent averse prognostic factors for SCS patients in DSS and OS. Despite the lack of the information about other treatment modalities (radiotherapy or chemotherapy), surgical resection shows the mainstay of treatment modality.

Materials and Methods {#Sec6}
=====================

The data extraction and statistical analysis were performed as described previously^[@CR19],[@CR20]^. In brief, the data were extracted with International Classification of Diseases for Oncology codes 8801/3 for SCS from 1973 to 2017 by using official software SEER\*Stat, version 8.3.4. Overall statistical analysis was performed by utilizing the software of the Statistical Package for Social Sciences, version 23.0, for Windows (SPSS, Chicago, IL) and survival tabs were generated by GraphPad Prism, version 5.01. The survival curves were generated by using the Kaplan-Meier method, and the survival difference was evaluated by performing the log-rank test. Adjusted hazard ratios (HRs) along with 95% confidence intervals (CIs) were calculated by using the Cox proportional hazards regression model. Differences in the numerical variables were assessed using the Student's test or non-parametric Wilcoxon test. Categorical variables comparisons were evaluated by the chi square test or Fisher exact test. When the P value was \<0.05, the difference was regarded as statistically significant. All statistical tests were two tailed.
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